Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC)

Carolyn Vachani, RN, MSN, AOCN
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 8 de junio del 2009

Translation for this article does not exist

Blogs

Healing Paws: Claire, Elise, Kim, Don and Finn
by OncoLink Editorial Team
February 09, 2016